Evidence map›Paper›PMID 35242571›Full record

ArticleMolecular genetics and metabolism reports2022

Sjögren-Larsson syndrome: A biochemical rationale for using aldehyde-reactive therapeutic agents.

William B Rizzo, Dana S'aulis, Elizabeth Dorwart, Zachary Bailey

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular genetics and metabolism reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05443685 (An Open-Label, Phase 1/2, Single-Site Study of the Safety, Biochemical Efficacy, and Exploratory Clinical Effects of Oral ADX-629 in Subjects With Sjögren-Larsson Syndrome), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05443685 phase1 / phase2completednot on this mapstarted 2023, after this paper: background citation

An Open-Label, Phase 1/2, Single-Site Study of the Safety, Biochemical Efficacy, and Exploratory Clinical Effects of Oral ADX-629 in Subjects With Sjögren-Larsson Syndrome

TypeinterventionalSponsorUniversity of NebraskaRan2023 to 2026Enrolled8ConditionsSjogren-Larsson SyndromeArmsADX-629
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Central Precocious Puberty and Sjogren-Larsson Syndrome in a Child: A Rare Case Report.Clinical, cosmetic and investigational dermatology · 2026
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

William B RizzoChild Health Research Institute, Omaha, NE, USA.
Dana S'aulisDepartment of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA.
Elizabeth DorwartDepartment of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA.
Zachary BaileyDepartment of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA.
University of Nebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sjögren-Larsson syndrome (SLS) is a neurocutaneous disease caused by mutations in

Indexed as

ADX-102ADX-102, [2-(3-amino-6-chloro-quinolin-2-yl)-propan-2-ol]Aldehyde adductC16:0-al, hexadecanalC16:1-al, 2-hexadecenalC18:0-al, octadecanalCHO, Chinese hamster ovaryFALDH, fatty aldehyde dehydrogenaseFatty alcoholFatty aldehydeMetabolismN-16:0-PE, N-hexadecanyl-phosphatidylethanolamineN-18:0-PE, N-octadecanyl-phosphatidylethanolamineNAE, N-alkyl-ethanolamineNAPE, N-alkyl-phosphatidylethanolaminePE, phosphatidylethanolamineSLS, Sjögren-Larsson syndrome.

Identifiers

PMID35242571
PMCPMC8856915
OpenAlexW4200490380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.